Transcend-T2D-2

Summary

This study will research a new diabetes medication. These medications are called incretins (retatrutide versus semaglutide). Everyone in this study will receive the investigative medication. The study will look at whether blood sugar control gets better. It will also look at whether weight change helps blood pressure and lab tests get better. Adults living with Type 2 diabetes will be included. They should be taking metformin 1500mg/day or more, with or without an SGLT2-i medication. A1c% should be stable at 7.0-10.5%. Everyone in this study will have counselling for healthy exercise and dietary behaviors. Study visits happen approximately once a month. There will be a total of 26 visits over 80 weeks. There is a possibility of the study being extended.

Eligibility

Currently recruiting participants: Yes

Eligible ages: 18 to 100

Accepts healthy participants: Yes

Inclusion criteria:

Inclusion:
1) Type 2 Diabetes
2) Must be taking ≥ 1500mg metformin daily
3) May also be taking an SGLT2i for diabetes ("gliflozin")
4) Have a HbAc1% between 7.0-10.5 on recent labs
5) Have stable weight for the last 90 days
6) Have no intention to lose weight or planned weight loss support outside of this study
7) Must have a height to weight ratio, or body mass index (BMI) of ≥ 25

Exclusion criteria:

Exclusion:
1) May not be taking any other diabetes medications (other than metformin and SGLT2i)
2) May not have diabetic eye disease requiring treatment
3) May not have surgery for obesity
4) Serious heart condition or recent heart event
5) Some people with gut or bowel issues may be excluded after talking to the team
6) May not have advanced kidney disease

Participate

Fill out the following form if you want to participate in this research

Method of contact

Collection of personal information
Your personal information is collected under the authority of section 33(c) of the Freedom of Information and Protection of Privacy Act. If you have any questions about the collection or use of this information, please visit our Access to Information page.

Additional information

Contact information

Michelle Smith

Principal investigator:

Ronald Sigal

Clinical trial:

Yes

REB-ID:

REB24-0229